Illumina Closes Acquisition of Grail Despite Ongoing Regulatory Review
- August 20, 2021
Illumina Inc., a genetic sequencing firm, has completed its $7.1 billion acquisition of cancer detection company Grail but will hold the company separate during the European Commission’s ongoing regulatory review.
ARTICLE TAGS
You must be logged in to access this content.